CN107973764A - Andrographolide class compound, its preparation method, pharmaceutical composition and application - Google Patents

Andrographolide class compound, its preparation method, pharmaceutical composition and application Download PDF

Info

Publication number
CN107973764A
CN107973764A CN201710997767.XA CN201710997767A CN107973764A CN 107973764 A CN107973764 A CN 107973764A CN 201710997767 A CN201710997767 A CN 201710997767A CN 107973764 A CN107973764 A CN 107973764A
Authority
CN
China
Prior art keywords
alkyl
substituted
unsubstituted
substitution
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201710997767.XA
Other languages
Chinese (zh)
Other versions
CN107973764B (en
Inventor
裴钢
高大新
刘凤涛
李伟
蒋春红
王章伟
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangxi Qingfeng Pharmaceutical Co ltd
Original Assignee
JIANGXI QINGFENG PHARMACEUTICAL CO Ltd
Shanghai de Novo Pharmatech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by JIANGXI QINGFENG PHARMACEUTICAL CO Ltd, Shanghai de Novo Pharmatech Co Ltd filed Critical JIANGXI QINGFENG PHARMACEUTICAL CO Ltd
Publication of CN107973764A publication Critical patent/CN107973764A/en
Application granted granted Critical
Publication of CN107973764B publication Critical patent/CN107973764B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/60—Two oxygen atoms, e.g. succinic anhydride
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention discloses a kind of andrographolide class compound, its preparation method, pharmaceutical composition and application.Andrographolide class compound (I), its isomers, prodrug, solvate or the pharmaceutically acceptable salt of the present invention has such as lower structure.The andrographolide class compound of the present invention has the function that good treatment inflammation disease, and the inflammation disease including but not limited to may be caused by the pathogen such as bacterium, virus, or the inflammation disease as caused by autoimmunity.

Description

Andrographolide class compound, its preparation method, pharmaceutical composition and application
Technical field
The present invention relates to a kind of andrographolide class compound, its isomers, prodrug, solvate or pharmaceutically acceptable Salt, its pharmaceutical composition, preparation method and application.
Background technology
Andrographolide (andrographolide) is one of highest component of content in Andrographis Paniculata.It has Multiple target effect mechanism, therefore, has extensive pharmacological activity, such as antipyretic, anti-inflammatory, analgesia, antibacterial, hypoglycemic etc., with The research that deepens continuously to andrographolide pharmacological action, finds it in immunological regulation, antiviral and antitumor etc. have It is widely used and (wears Gui Fu etc., Chinese patent drug, 2006,28 (7):1032).Andrographolide concrete structure is as follows：
At present, there are document and patent report (Lin HQ, et al.Biol.Pharm.Bull.2006,29 (2):220, CN101012211B, CN1666985A, US20050215628A1), andrographolide and its derivative can suppress LPS inductions TNF-α, IL1 β and IL-6 expression, so as to suppress the inflammatory reaction of body.TNF-α is a kind of precursor inflammatory cytokine, Participate in many inflammatory reaction processes.It can be used for treatment various autoimmune disease (rheumatoid joint by suppressing TNF-α Inflammation, Crohn disease, systemic loupus erythematosus, psoriasis etc.), the nervous system disease (Alzheimer's disease, Parkinson's, AIDS Dementia, depression), (Ogata H, the Hibi T.et al.Curr Pharm such as cancer and respiratory virus infection Des.2003,9(14):1107；Sack M.et al.Pharmacol Ther.2002,94(1-2):123-135；Barnes PJ.Et al.Annu Rev Pharmacol Toxicol.2002,42:81；Goldring MB.Et al.Expert Opin Biol Ther.2001Sep；1(5):817).IL1 β are by generations such as mononuclear macrophage, dendritic cells and fibroblasts Cell factor, can stimulate propagation and the differentiation of T cell and B cell, participate in inflammatory reaction.Suppressing IL1 β can be used for treatment to include disease Various inflammatory reactions (Taylor PC.et al.Curr Pharm Des.2003 including poison infection；9(14):1095； Dellinger RP et al Clin Infect Dis.2003May 15；36(10):1259).IL-6 is also known as B cell thorn Swash the factor, various kinds of cell can be spontaneous or produce IL-6 under other stimulations, its periphery and development of central nervous system, differentiation, Play an important role in regeneration and denaturation.
In addition, found that andrographolide and its derivative had certain effect in terms of viral infection resisting in recent years, its Had made some progress in terms for the treatment of and preventing AIDS, hepatitis and the infection of hand-foot-and-mouth disease virus.Such as CN103739575A and CN103739597A discloses the anti-HBV effect of andrographolidume derivative.CN104042621A is disclosed in Herba Andrographitis Esters medicine-Xiyanping has the serious consequence prevented and mitigated caused by hand-foot-and-mouth disease virus infection, but Xiyanping is to wear The sulfonated products of heart lotus lactone, not single structure, therefore machine further to define using the micromolecular compound of single structure Reason, is of great significance its drug effect and its toxicologic study.
In summary, although andrographolide class compound has obtained some developmental achievements, for a variety of diseases, especially Its anti-inflammatory and antiviral field are still used for clinic without particularly effective andrographolide analog.Through retrieval, find no By in 17 double-bond rearrangements of andrographolide to diterpene ring, and introduce at 14 hydroxyls ester bond or ehter bond formed it is new similar Thing, and for anti-inflammatory and the report in antiviral field.
The content of the invention
The technical problems to be solved by the invention are, there is provided a kind of new andrographolide class compound, its preparation Method, pharmaceutical composition and application.The andrographolide class compound of the present invention has good anti-inflammatory effect, can effectively control Treat inflammation disease.Signified inflammation disease of the invention includes but not limited to may be caused by the pathogen such as bacterium, virus, by certainly Caused by body is immunized, or inflammation disease caused by radiation damage.
The present invention provides a kind of andrographolide class compound (I), its isomers, prodrug, solvate or pharmaceutically Acceptable salt；
Wherein,
A and b is separately singly-bound or double bond, and is double bond or singly-bound during a and b differences；
X is-OR5Or-SR6；
Y and Z is separately selected from-O- or-NH-；
R1And R2Separately it is selected from hydrogen or alkyl；
R3And R4Separately selected from hydrogen, alkyl, haloalkyl ,-Si (Rc)3、-C(O)Rc、-SO3M；M for hydrogen, sodium or Potassium；Or R3And R45-8 membered heterocycloalkyls are interconnected to form, the Heterocyclylalkyl can also be further selected from containing 1~2 Si、S(O)0-2Or the hetero atom or group of N atoms；The Heterocyclylalkyl is unsubstituted or is further selected from alkane by 1~4 The substituent substitution of base, halogen, haloalkyl, hydroxy alkyl, alkoxyalkyl, alkoxy, amino, aminoalkyl or oxo base At an arbitrary position；
R5For substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted Heterocyclylalkyl, take It is generation or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyl-alkyl, substituted or unsubstituted Hetercycloalkylalkyl, substituted or unsubstituted aryl alkyl, substituted or unsubstituted heteroaryl alkyl, Ra、-C(O)Rb、-C(O) NRbRc、-C(O)ORc、-S(O)2Rb、-S(O)2NRcRd、-NRcRd、-(CH2)nORa；
R6For hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycle alkane Base, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyl-alkyl, substitution or not Substituted hetercycloalkylalkyl, substituted or unsubstituted aryl alkyl, substituted or unsubstituted heteroaryl alkyl ,-C (O) Rb、-C (O)NRbRc、-C(O)ORcOr-(CH2)nORa；
R5Or R6In, when the substituted alkyl, the cycloalkyl of substitution, the Heterocyclylalkyl of substitution, the aryl of substitution, substitution Heteroaryl, substitution cycloalkyl-alkyl, substitution hetercycloalkylalkyl, substitution aryl alkyl or substituted heteroaryl alkane Base can be by 1~4 selected from halogen, C when substituted1-4Alkyl, halo C1-3Alkyl, C1-3Alkoxy, halo C1-3Alkoxy, C2-6 Alkenyl, C2-6Alkynyl, C3-6Cycloalkyl, 3-6 membered heterocycloalkyls, phenyl, 5-6 unit's heteroaryls ,-NO2、-CN、-ORc、-SRc、-OC (O)Rc、-OC(O)NRcRd、-NRcRd、-N(Rc)C(O)Rd、-N(Rc)S(O)2Rd、-N(Rc)S(O)2NRcRd、-N(Rc)C(O) NRcRd、-S(O)2NRcRd、-S(O)0-2Rc、-OP(O)(O-Rc)2、-C(O)Rc、-C(O)ORcOr-C (O) NRcRdSubstituent take In generation, is at an arbitrary position；N is 1~6 integer；
RaFor glycyl-, L- alanyls-, L- leucyls-, L- valyls-, L- isoleucyl-s-, etc. amino acid residue；
RbFor hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycle alkane Base, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyl-alkyl, substitution or not Substituted hetercycloalkylalkyl, substituted or unsubstituted aryl alkyl, substituted or unsubstituted heteroaryl alkyl；When the substitution Alkyl, substitution cycloalkyl, substitution Heterocyclylalkyl, substitution aryl, substitution heteroaryl, substitution cycloalkyl-alkyl, Substituted hetercycloalkylalkyl, the aryl alkyl of substitution or substituted heteroaryl alkyl can be selected from halogen when being substituted by 1~4 Element, C1-4Alkyl, halo C1-3Alkyl, C1-3Alkoxy, halo C1-3Alkoxy, C2-6Alkenyl, C2-6Alkynyl, C3-6Cycloalkyl, 3-6 Membered heterocycloalkyl, phenyl, 5-6 unit's heteroaryls ,-NO2、-CN、-ORc、-SRc、-OC(O)Rc、-OC(O)NRcRd、-NRcRd、-N (Rc)C(O)Rd、-N(Rc)S(O)2Rd、-N(Rc)S(O)2NRcRd、-N(Rc)C(O)NRcRd、-S(O)2NRcRd、-S(O)0-2Rc、- OP(O)(O-Rc)2、-C(O)Rc、-C(O)ORcOr-C (O) NRcRdSubstituent substitution at an arbitrary position；
RcAnd RdSeparately selected from hydrogen, C1-6Alkyl, halo C1-3Alkyl, C1-3Alkoxy, halo C1-3Alkoxy, C2-6 Alkenyl, C2-6Alkynyl, C3-6Cycloalkyl, 3-6 membered heterocycloalkyls, phenyl or 5-6 unit's heteroaryls.
Alternatively, RcAnd RbOr RdWith forming 3-8 membered heterocycloalkyls, the Heterocyclylalkyl together with the N atoms that they are connected jointly Also further N, O, S, S (O) can be selected from containing 1~32Hetero atom, the 3-8 membered heterocycloalkyls are unsubstituted or into one Step is selected from alkyl, halogen, haloalkyl, hydroxy alkyl, alkoxyalkyl, alkoxy, amino, aminoalkyl or oxygen by 1~3 The substituent substitution of Dai Ji is at an arbitrary position.
The R1Preferably hydrogen or C1-6Alkyl；The R1More preferably H.
The R2Preferably hydrogen or C1-6Alkyl；The R2More preferably methyl.
The R3Preferably hydrogen, C1-6Alkyl, halo C1-3Alkyl ,-Si (Rc)3、-C(O)Rc、-SO3M；M is hydrogen, sodium or potassium； The R3More preferably hydrogen.
The R4Preferably hydrogen, C1-6Alkyl, halo C1-3Alkyl ,-Si (Rc)3、-C(O)Rc、-SO3M；M is hydrogen, sodium or potassium； The R4More preferably hydrogen.
Or the R3And R45-8 membered heterocycloalkyls are interconnected to form, the Heterocyclylalkyl can also further contain 1- 2 are selected from Si, S (O)0-2Or the hetero atom of N atoms；The Heterocyclylalkyl is unsubstituted or is further selected from C by 1-31-4 Alkyl, halogen, halo C1-3Alkyl, hydroxyl C1-3Alkyl, C1-3Alkoxy C1-3Alkyl, C1-3Alkoxy, amino, amino C1-3Alkyl Or the substitution of one or more of substituent of oxo base is at an arbitrary position.
The R5Preferably substituted or unsubstituted C1-6Alkyl, substituted or unsubstituted C3-8Cycloalkyl, substitution do not take It is the 3-8 membered heterocycloalkyls in generation, substituted or unsubstituted phenyl, substituted or unsubstituted 5-6 unit's heteroaryls, substituted or unsubstituted C3-8Cycloalkyl C1-3Alkyl, substituted or unsubstituted 3-8 membered heterocycloalkyls C1-3Alkyl, substituted or unsubstituted phenyl C1-3Alkane Base, substituted or unsubstituted 5-6 unit's heteroaryls C1-3Alkyl, Ra、-C(O)Rb、-C(O)NRbRc、-C(O)ORc、-S(O)2Rb、-S (O)2NRcRd、-NRcRdOr-(CH2)nORa。
The R6Preferably substituted or unsubstituted C1-6Alkyl, substituted or unsubstituted C3-8Cycloalkyl, substitution do not take It is the 3-8 membered heterocycloalkyls in generation, substituted or unsubstituted phenyl, substituted or unsubstituted 5-6 unit's heteroaryls, substituted or unsubstituted C3-8Cycloalkyl C1-3Alkyl, substituted or unsubstituted 3-8 membered heterocycloalkyls C1-3Alkyl, substituted or unsubstituted phenyl C1-3Alkane Base, substituted or unsubstituted 5-6 unit's heteroaryls C1-3Alkyl ,-C (O) Rb、-C(O)NRbRc、-C(O)ORcOr-(CH2)nORa。
The RbPreferably substituted or unsubstituted C1-6Alkyl, substituted or unsubstituted C3-8Cycloalkyl, substitution do not take It is the 3-8 membered heterocycloalkyls in generation, substituted or unsubstituted phenyl, substituted or unsubstituted 5-6 unit's heteroaryls, substituted or unsubstituted C3-8Cycloalkyl C1-3Alkyl, substituted or unsubstituted 3-8 membered heterocycloalkyls C1-3Alkyl, substituted or unsubstituted phenyl C1-3Alkane Base or substituted or unsubstituted 5-6 unit's heteroaryls C1-3Alkyl.
Andrographolide class compound, its isomers, prodrug, hydrate, solvate as shown in formula (I) or pharmaceutically Acceptable salt；
In wherein a kind of preferred embodiment, when a is double bond, b is singly-bound；
In wherein a kind of preferred embodiment, when a is singly-bound, b is double bond.
In a currently preferred embodiment, the andrographolide class compound (I), its isomers, prodrug, Solvate or pharmaceutically acceptable salt, its general formula is more preferably such as lower structure：
Wherein, * is expressed as R configurations or S configurations；
R2、R3、R4And R5Definition as described above；
Various situations are included in the definition of structural formula (IA) below：
In wherein a kind of preferred embodiment, R2For CH3；
In wherein a kind of preferred embodiment, R3For H, R4For H.
In a currently preferred embodiment, the andrographolide class compound (I), its isomers, prodrug, Solvate or pharmaceutically acceptable salt, its general formula is more preferably such as lower structure：
Wherein, * is expressed as R configurations or S configurations；
A rings are phenyl ring or 5-6 member hetero-aromatic rings；
R7For halogen, C1-4Alkyl, halo C1-3Alkyl, C1-3Alkoxy, halo C1-3Alkoxy, C2-6Alkenyl, C2-6Alkynyl, C3-6Cycloalkyl, 3-6 membered heterocycloalkyls, phenyl, 5-6 unit's heteroaryls ,-NO2、-CN、-ORc、-SRc、-OC(O)Rc、-OC(O) NRcRd、-NRcRd、-N(Rc)C(O)Rd、-N(Rc)S(O)2Rd、-N(Rc)S(O)2NRcRd、-N(Rc)C(O)NRcRd、-S(O)2NRcRd、-S(O)0-2Rc、-OP(O)(O-Rc)2、-C(O)Rc、-C(O)ORcOr-C (O) NRcRd；
T is 1,2 or 3；
R1、R2、R4、RcAnd RdIt is defined as described above.
Various situations are included in the definition of structural formula (IB) below：
In wherein a kind of preferred embodiment, R2For CH3；
In wherein a kind of preferred embodiment, R3For H, R4For H.
In a currently preferred embodiment, the andrographolide class compound (I), its isomers, prodrug, Solvate or pharmaceutically acceptable salt, its general formula is more preferably such as lower structure：
Wherein, * is expressed as R configurations or S configurations；
R2、R3、R4、RbAnd RcDefinition as described above；
Various situations are included in the definition of structural formula (IC) or (ID) below：
In wherein a kind of preferred embodiment, R2For CH3；
In wherein a kind of preferred embodiment, R3For H, R4For H.
Andrographolide class compound (I), its isomers, prodrug, solvate or the pharmaceutically acceptable salt are most It is following any structure goodly：
Present invention also offers andrographolide class compound (I), its isomers, prodrug, solvate or the pharmacy The preparation method of upper acceptable salt, it is following any method：
Method 1：
Wherein, R ' is phenyl, and R " is H；Or R ' and R " is methyl；*、RbOr RcIt is defined as described above.
Include the following steps in method 1：Step 1, in solvent, by compound 1.2 and the carbamyl chloride or acyl chlorides of substitution In alkaline conditions, reaction obtains compound I-1 or I-2 in non-protonic solvent；Step 2, in solvent, under acid condition, I-1 or I-2 obtains compound Ia or Ib by de- double hydroxyl protection bases.
In method 1, the condition and step of the reaction can be the condition and step of this area routine, and the present invention is especially excellent Select following reaction condition：Step 1, the alkali is preferably triethylamine, the preferred dichloromethane of the non-protonic solvent, described The dosage of non-protonic solvent preferably 1~50mL/mmol compounds 1.2, temperature preferably 0 DEG C-room temperature, reaction time preferred 0-24 Hour, compound 1.2 and N (Rb)(Rc) COCl or RbThe molar ratio of COCl preferably 1:1~1:3, described 1.2 rub with triethylamine That ratio preferably 1:1~1:10, to accelerate reaction speed, the 4- dimethylamino pyrroles of 0.1~1 equivalent can be also added in the reaction system Pyridine (DMAP)；Step 2, the deprotection reaction is routinely deprotected condition for this area, for example, can take off in acid condition Remove, when R ' and R " they are methyl, preferred aqueous acetic acid；The aqueous acetic acid preferred volume percentage is 75~85% vinegar Aqueous acid；The dosage of the aqueous acetic acid preferably 5~20mL/mmol compound I-2 or I-3, the reaction temperature are preferred 20~50 DEG C, when the reaction time preferably 0.2~2 is small.R ' is phenyl, when R " is H, preferably in ethanol solution, in a hydration pair Deprotection reaction is carried out in the presence of toluenesulfonic acid, wherein, the dosage of the ethanol be preferably 1~50mL/mmol compounds I-1 or I-2；The molar ratio of the hydration p-methyl benzenesulfonic acid of compound I-1 or I-2 and one is preferably 1:1~1:3, more preferably 1:2；It is described anti- Answer preferably 20~70 DEG C of temperature, preferably 1~3 day reaction time.
Method 2：
Wherein, R ' is phenyl, and R " is H；Or R ' and R " is methyl；*, A rings, R7It is defined as described above with t.
Include the following steps in method 2：Step 1, in solvent, by 1.2 He of compoundIt is anti-by Mitsunobu It should obtain compound I-3；Step 2, in solvent, under acid condition, I-3 is taken off into double hydroxyl protection bases and obtains compound Ic.
In method 2, the condition and step of the reaction can be the condition and step of this area routine, and the present invention is especially excellent Select following reaction condition：Step 1, Mitsunobu reaction triphenylphosphines and diisopropyl azodiformate (DIAD) combine, 1.2 He of compoundMolar ratio preferably 1:0.9~1:2；The triphenylphosphine, DIAD andMolar ratio preferably 1:1:1~1:2:2；Reaction temperature preferably 0 DEG C~room temperature；Step 2, the deprotection reaction is This area is routinely deprotected condition, for example, can remove in acid condition, when R ' and R " are methyl, preferably acetic acid is water-soluble Liquid；The aqueous acetic acid preferred volume percentage is 75~85% aqueous acetic acid；The dosage of the aqueous acetic acid is excellent Select 5~20mL/mmol compound I-2 or I-3, preferably 20~50 DEG C of the reaction temperature, when the reaction time preferably 0.2~2 is small. R ' is phenyl, and when R " is H, preferably in ethanol solution, deprotection reaction is carried out in the presence of a hydration p-methyl benzenesulfonic acid, its In, the dosage of the ethanol is preferably 1~50mL/mmol compounds I-1 or I-2；The hydrations of compound I-1 or I-2 and one are to first The molar ratio of benzene sulfonic acid is preferably 1:1~1:3, more preferably 1:2；Preferably 20~70 DEG C of the reaction temperature, the reaction time is excellent Select 1~3 day.
In method one or two, 1.2 synthetic method of compound is as follows：
Wherein, R ' is phenyl, and R " is H；Or R ' and R " is methyl；
1.2 synthetic method of compound includes the following steps：Step 1, in solvent, by andrographolide in hydrogen bromide Act on lower 17 double bonds generation rearrangement reaction and obtain compound 1.1；Step 2, by 3 of compound 1.1 and 19 hydroxyl protections, Generally preferably use acetone and 2,2-dimethoxypropane system, or benzaldehyde dimethyl acetal and para-methylbenzenepyridinsulfonate sulfonate hydrochlorate body System.
In 1.2 synthetic method of compound, the condition and step of the reaction can be the condition and step of this area routine, Following reaction condition specifically preferred according to the invention：Step 1, the solvent preferred alcohol, dosage preferably 1~50mL/ of the solvent Mmol andrographolides, the hydrogen bromide preferred mass percentage, 46~48% aqueous solution of hydrogen bromide, the hydrogen bromide water The volume ratio of solution and solvent preferably 0.5:1~1:1, the reaction temperature preferably 0 DEG C~room temperature, the reaction time preferably 1~24 Hour；Step 2, the hydroxyl protection reaction is routinely deprotected condition for this area.It is preferred that with acetone and 2,2- dimethoxys third Alkane system, dosage preferably 0.5~5mL/mmol compounds 1.1 of the acetone, the dosage of the 2,2-dimethoxypropane is excellent Select 1~10mL/mmol compounds 1.1, preferably 30~60 DEG C of temperature, when the reaction time preferably 2~10 is small；It is preferred that with benzaldehyde two Dimethoxym ethane and para-methylbenzenepyridinsulfonate sulfonate silicate system, wherein solvent are preferably dichloromethane；The benzaldehyde dimethyl acetal and The molar ratio of compound 1.1 is preferably 1:1~1:3, more preferably 1:2；The dosage of the para-methylbenzenepyridinsulfonate sulfonate hydrochlorate is Catalytic amount, and the molar ratio of compound 1.1 is preferably 1:0.02~1:0.1, the preferred room temperature of temperature, the reaction time preferably 10~24 Hour；
The pharmaceutically acceptable salt of the andrographolide class compound (I) can be chemically synthesized by general.
Under normal circumstances, the preparation of salt can by free alkali or acid with etc. chemical equivalent or excess acid (inorganic acid or Organic acid) or alkali (inorganic base or organic base) reacted in suitable solvent or solvent compositions be made.
Present invention also offers a kind of pharmaceutical composition, it includes the active component of therapeutically effective amount and can pharmaceutically connect The auxiliary material received；The active component includes andrographolide class compound (I), its isomers, prodrug, solvate and pharmaceutically One or more in acceptable salt.
In described pharmaceutical composition, the active component may also include the other treatments for suppressing inflammation or virus infection etc. Agent.
In described pharmaceutical composition, the pharmaceutically acceptable auxiliary material may include pharmaceutically acceptable carrier, dilution Agent and/or excipient.
According to therapeutic purposes, pharmaceutical composition can be made to various types of administration unit dosage forms, such as tablet, pill, powder Agent, liquid, suspension, lotion, granule, capsule, suppository and injection (solution and suspension) etc., preferred liquid, suspension, breast Liquid, suppository and injection (solution and suspension) etc..
In order to shape the pharmaceutical composition of tablet form, it can be used this area any known and widely used figuration Agent.For example, carrier, such as lactose, white sugar, sodium chloride, glucose, urea, starch, calcium carbonate, kaolin, avicel cellulose and silicon Acid etc.；Adhesive, such as water, ethanol, propyl alcohol, common syrup, glucose solution, starch solution, gelatin solution, carboxymethyl cellulose Element, lac, methylcellulose and potassium phosphate, polyvinylpyrrolidone etc.；Disintegrant, such as dried starch, mosanom, agar powder and sea Band powder, sodium acid carbonate, calcium carbonate, the fatty acid ester of polyethylene sorbitan, lauryl sodium sulfate, stearic acid monoglycerides, Starch and lactose etc.；Disintegration inhibitor, such as white sugar, glycerol tristearate, coconut oil and hydrogenated oil and fat；Adsorption enhancer, such as season Amine base and lauryl sodium sulfate etc.；Wetting agent, such as glycerine, starch；Adsorbent, such as starch, lactose, kaolin, bentonite With colloid silicic acid etc.；And lubricant, such as pure talcum, stearate, boric acid powder and polyethylene glycol etc..Can also be according to need Select common coated material be made sugar coated tablet, apply gelatin film tablet, enteric coated tablets, film coated tablets, duplicature tablet and Multilayer tablet.
In order to shape the pharmaceutical composition of pill, it can be used this area any of and widely used figuration Agent, for example, carrier, such as lactose, starch, coconut oil, hardened vegetable oils, kaolin and talcum powder etc.；Adhesive, such as Arabic tree Rubber powder, tragacanth gum powder, gelatin and ethanol etc.；Disintegrant, such as agar and Kelp Powder.
In order to shape the pharmaceutical composition of suppository form, it can be used this area any known and widely used inborn nature Agent, for example, polyethylene glycol, coconut oil, higher alcohol, the ester of higher alcohol, gelatin and semi-synthetic glyceride etc..
In order to prepare the pharmaceutical composition of injection form, (suitable chlorine can will be preferably added after solution or suspension liquid disinfectant Change sodium, glucose or glycerine etc.), it is made and the isotonic injection of blood.When preparing injection, it is possible to use in the art any Common carrier.For example, water, ethanol, propane diols, the isooctadecanol of ethoxylation, the isooctadecanol and polyethylene of polyoxy Fatty acid ester of anhydro sorbitol etc..In addition, it can also add common lytic agent, buffer and anodyne etc..
In the present invention, content of the composition in pharmaceutical composition is without specifically limited, wherein in the Herba Andrographitis Ester type compound (I), its isomers, prodrug, solvate or pharmaceutically acceptable salt can be selected in a wide range To select, safely, effectively dosage is determined according to concrete conditions such as the age for the treatment of target, weight, the state of an illness, the course of disease, methods of administration for it, The 5~95% of mass percent are generally can be, are preferably mass percent 30~80%.
In the present invention, the medication of described pharmaceutical composition is not particularly limited.Can according to patient age, gender and its Its condition and symptom, select the preparation of various formulations to be administered.For example, tablet, pill, solution, suspension, lotion, granule or Capsule oral is administered；Injection can be administered alone, or mixed with injection conveying liquid (such as glucose solution and Freamine Ⅲ) Conjunction is injected intravenously；Suppository is to be administered into rectum.
Present invention also offers andrographolide class compound (I), its isomers, prodrug, solvate or the pharmacy Upper acceptable salt, or described pharmaceutical composition, inflammation is treated preparing, including is caused by pathogenic infections such as bacterium, viruses Inflammation, the purposes in inflammation disease caused by autoimmune response, and the medicine of inflammation caused by radiation damage etc..Its Described in virus include：The various viruses of hand-foot-and-mouth disease are (for example, cause most common enterovirus EV71, Ke Sa of hand-foot-and-mouth disease Strange virus CA16 etc.), various hepatitis viruses (for example, hepatitis A, hepatitis B, hepatitis C virus), AIDS virus etc..
Inflammation disease caused by the autoimmune response, including：Rheumatoid arthritis, systemic lupus erythematosus, Mixed connective tissue disease (MCTD), system chorionitis (including：CREST syndromes), dermatomyositis, nodular vasculitis, nephrosis (including：Empsyxis nephrotic syndrome, acute glomerulonephritis, primary membranoproliferative glomerulonephtitis etc.), primary biliary Property hepatic sclerosis, autoimmune cholangitis, oneself immunity hepatitis, primary sclerotic cholangitis, inflammatory bowel disease (IBD) (bag Include：Crohn disease (CD) and ulcerative colitis (UC)), chronic obstructive pulmonary disease etc..
The radioactive inflammation disease, including：Radiation esophagitis, radiation enteritis, radiation thyroiditis, radioactivity Osteitis, Inflammation of Radioactive Oral Cavity, radiation_induced pleurisy, radiodermatitis, radiation pneumonitis, radioactivity vaginitis, radioactivity bladder Inflammation etc..
Present invention also offers andrographolide class compound (I), its isomers, prodrug, solvate or the pharmacy Upper acceptable salt and one or more other species therapeutic agents are used to treat inflammation, virus infection, autoimmune disease Disease, and/or radioactivity damage.
Present invention also offers andrographolide class compound (I), its isomers, prodrug, solvate or the pharmacy Upper acceptable salt and one or more other species therapeutic agents are used to prepare treatment inflammation, virus infection, autoimmunity Application in the medicine of property disease or radiation damage.
The therapeutic agent of other species can with the andrographolide class compound (I), its isomers, prodrug, Solvate or pharmaceutically acceptable salt, or described pharmaceutical composition, make the therapeutic dosage forms of single administration, or respectively The therapeutic dosage forms of consecutive administration.
In the present invention, unless otherwise indicated, do not referred both to not labeled with what " substituted or unsubstituted " defined before substituent title Substituted situation, such as：" alkyl " refers to unsubstituted alkyl, and " cycloalkyl " refers to unsubstituted cycloalkyl.
Unless otherwise indicated, the following term occurred in description of the invention and claims has following implications：
Term " alkyl " refers to saturated straight chain or branched hydrocarbyl comprising 1-20 carbon atom, preferably 1-10 carbon atom, More preferably 1-8,1-6,1-4,1-3 carbon atoms, the representative example of alkyl include but not limited to：Methyl, ethyl, n-propyl, Isopropyl, normal-butyl, sec-butyl, the tert-butyl group, isobutyl group, amyl group, hexyl, heptyl, octyl group, nonyl, decyl, 4,4- dimethyl-pentens Base, 2,2,4- tri-methyl-amyls, undecyl, dodecyl, and their various isomers etc..When " alkyl " is used as other bases During the linking group of group, such as-(CH2)m-, it can be straight or branched, and example includes but not limited to-CH2-、-CH2CH2-、- CH2CH(CH3)-。
Term " cycloalkyl " refers to the saturation comprising 3-20 carbon atom or part unsaturation (including 1 or 2 double bond) One or more cyclic groups.It is preferred that 3-12 member cycloalkyl." monocyclic cycloalkyl " preferably 3-10 unit monocycle alkyl, more preferably 3-8 members are single Cycloalkyl, such as：Cyclopropyl, cyclobutyl, cyclopenta, cyclohexyl, suberyl, cyclooctyl, cyclodecyl, cyclo-dodecyl, hexamethylene Alkenyl." polycyclic naphthene base " includes " bridged ring base ", " fused cycloalkyl " and " spiro cycloalkyl group ", the representative example bag of " bridged ring base " Include but be not limited to：It is bornyl, bicyclic [2.2.1] heptenyl, bicyclic [3.1.1] heptane base, bicyclic [2.2.1] heptane base, bicyclic [2.2.2] octyl, bicyclic [3.2.2] nonyl, bicyclic [3.3.1] nonyl, bicyclic [4.2.1] nonyl and adamantyl Deng." fused cycloalkyl ", which includes, is fused to cycloalkyl ring on phenyl, cycloalkyl or heteroaryl, and fused cycloalkyl is included but not It is limited to：Benzocyclobutene, 2,3- dihydro -1-H- indenes, 2,3- cyclopenta pyridines, 5,6- dihydro -4H- cyclopenta [B] thiophene, ten Hydrogen naphthalene etc..The representative example of " spiro cycloalkyl group " includes but not limited to：Spiral shell [2,4] heptane base, spiral shell [4,5] decyl etc..It is monocyclic Cycloalkyl or polycyclic naphthene base can be connected on parent molecule by arbitrary carbon atom chain on ring.
Term " Heterocyclylalkyl " refers to by carbon atom and the saturation formed selected from hetero atoms such as nitrogen, oxygen or sulphur or part insatiable hunger The non-aromatic cyclic radical of (including 1 or 2 double bond), this cyclic group can be one or more cyclic groups, in the present invention, miscellaneous Hetero atom number preferably 1,2,3 or 4 in cycloalkyl, nitrogen, carbon or sulphur atom in Heterocyclylalkyl are optionally aoxidized.Nitrogen-atoms It optionally can further be substituted by other groups and form tertiary amine or quaternary ammonium salt." monocyclic heterocycloalkyl " preferably 3-10 unit monocycle heterocycles Alkyl, more preferably 3-8 unit monocycles Heterocyclylalkyl.Such as：'-aziridino, tetrahydrofuran -2- bases, morpholine -4- bases, thiomorpholine - 4- bases, thiomorpholine-S-oxide -4- bases, piperidin-1-yl, N- Alkylpiperidine -4- bases, pyrrolidin-1-yl, N- alkyl pyrroles Alkane -2- bases, piperazine -1- bases, 4- alkyl piperazine -1- bases etc.." polycyclic Heterocyclylalkyl " includes " annelated heterocycles alkyl ", " spiroheterocyclic Base " and " bridge Heterocyclylalkyl "." annelated heterocycles alkyl " includes and is fused to the monocyclic of phenyl, cycloalkyl, Heterocyclylalkyl or heteroaryl Heterocycloalkyl ring, annelated heterocycles alkyl include but not limited to：2,3- dihydro benzo furyls, 1,3- dihydroisobenzofurans base, Indolinyl, 2,3- dihydrobenzos [b] thienyl, dihydrobenzo piperazine are muttered base, 1,2,3,4- tetrahydric quinoline groups etc..Monocyclic heterocycles Alkyl and polycyclic Heterocyclylalkyl can be linked on parent molecule by arbitrary annular atom on ring.Above-mentioned annular atom refers in particular to form The carbon atom and/or nitrogen-atoms of ring skeleton.
Term " cycloalkyl-alkyl " refers to connect by alkyl between cycloalkyl and mother nucleus structure.Thus, " cycloalkyl alkane Base " includes the definition of abovementioned alkyl and cycloalkyl.
Term " hetercycloalkylalkyl " refers to connect by alkyl between Heterocyclylalkyl and mother nucleus structure.Thus, " heterocycle alkane Base alkyl " includes the definition of abovementioned alkyl and Heterocyclylalkyl.
Term " alkoxy " refers to has the carbon number purpose ring-type or acyclic alkyl groups, bag by what oxygen bridge connected Containing alkyl oxy, cycloalkyl oxy and Heterocyclylalkyl epoxide.Thus, " alkoxy " includes abovementioned alkyl, Heterocyclylalkyl and cycloalkanes The definition of base.
Term " alkoxyalkyl " refers to that any one hydrogen atom is substituted by alkoxy on alkyl.Thus, " alkoxy alkane Base " includes the definition of abovementioned alkyl and alkoxy.
Term " hydroxy alkyl " refers to that any one hydrogen atom is substituted by hydroxyl on alkyl, includes but not limited to：- CH2OH、-CH2CH2OH、-CH2CH2C(CH3)2OH。
Term " alkenyl " refers to the straight chain containing at least one carbon-carbon double bond, side chain or the non-aromatic alkyl of ring-type.Wherein can be with There are 1-3 carbon-carbon double bond, and preferably there are 1 carbon-carbon double bond.Term " C2-4Alkenyl " refers to the alkenyl with 2-4 carbon atom, Term " C2-6Alkenyl " refers to the alkenyl with 2-6 carbon atom, including vinyl, acrylic, cyclobutenyl, 2- methyl butene bases And cyclohexenyl group.The alkenyl can be substituted.
Term " alkynyl " refers to the straight chain containing at least one triple carbon-carbon bonds, side chain or cyclic hydrocarbon group.Wherein there may be 1-3 triple carbon-carbon bonds, preferably there are 1 triple carbon-carbon bonds.Term " C2-6Alkynyl " refers to the alkynyl with 2-6 carbon atom, including Acetenyl, propinyl, butynyl and 3- methylbutynyls.
Term " aryl " refers to the 6-10 unit monocycles or bicyclic aromatic groups of any stabilization, such as：Phenyl, naphthyl, four Hydrogen naphthyl, indanyl or xenyl etc..
Term " heteroaryl " refers to that the carbon atom at least one ring is formed by the hetero atom displacement selected from nitrogen, oxygen or sulphur Aromatic group, it can be 5-7 unit monocycles structure or 7-12 membered bicyclic structures, preferably 5-6 unit's heteroaryls.In the present invention, Hetero atom number preferably 1,2 or 3, including:Pyridine radicals, pyrimidine radicals, (2H) -one of pyridazine -3 base, furyl, thienyl, thiazolyl, Pyrrole radicals, imidazole radicals, pyrazolyl, oxazolyl, isoxazolyl, 1,2,5- oxadiazoles base, 1,2,4- oxadiazoles base, tri- nitrogen of 1,2,4- Oxazolyl, 1,2,3- triazol radicals, tetrazole base, indazolyl, iso indazolyl, indyl, isoindolyl, benzofuranyl, benzo Thienyl, benzo [d] [1,3] dioxolanyl, benzothiazolyl, benzoxazolyl, quinolyl, isoquinolyl, quinazolyl Deng.
Term " aryl alkyl " refers to connect by alkyl between aryl and mother nucleus structure.Thus, " aryl alkyl " includes The definition of abovementioned alkyl and aryl.
Term " heteroaryl alkyl " refers to connect by alkyl between Heterocyclylalkyl and mother nucleus structure.Thus, " heteroaryl alkane Base " includes the definition of abovementioned alkyl and heteroaryl.
Term " halogen " represents fluorine, chlorine, bromine or iodine.
Term " haloalkyl " refers to the alkyl arbitrarily substituted by halogen.Thus, " haloalkyl " include above halogen and The definition of alkyl.
Term " halogenated alkoxy " refers to the alkoxy arbitrarily substituted by halogen.Thus, more than " halogenated alkoxy " includes The definition of halogen and alkoxy.
Term " amino " refers to-NH2, term " alkylamino " refers to that at least one hydrogen atom is substituted by alkyl on amino, Including but not limited to：-NHCH2、-NHCH2CH3.Term " aminoalkyl " refers to that any one hydrogen atom is taken by amino on alkyl In generation, include but not limited to：-CH2NH2、-CH2CH2NH2.Thus, " aminoalkyl " and " alkylamino " includes abovementioned alkyl and amino Definition.
Term " amino acid residue " refers to that the carboxylic acid fragment containing amino is mutual by carboxyl and parent molecule formation acyl group Connection, the amino acid residue include natural or non-naturally occurring amino acid residue.It is preferred that naturally occurring amino acid residue, The amino acid includes but not limited to：Alanyl-, valyl-, L- alanyls-, L- leucyls-, L- isoleucyl-s-, dried meat ammonia Acyl-, phenylalanyl-, tryptophanyl-, methinyl-, glycyl-, seryl-, threonyl-, cysteinyl-, tyrosyl-, asparagus fern Acyl acyl --, glutamy acyl-, lysyl-, arginyl-, histidyl--, aspartoyl-or glutamy-.
Symbol "=" represents double bond；
" room temperature " of the present invention refers to 15-30 DEG C.
" prodrug " refers to that compound is converted into original activity compound after being metabolized in vivo.Typically say, it is preceding Medicine is inert matter, and either specific activity parent compound activity is small but can provide convenient operation, is administered or improve generation Thank to characteristic.
" solvate " of the present invention refers to the solvent addition form comprising stoichiometry or non-stoichiometry solvent. Some compounds tend to catch the solvent molecule of fixed molar ratio example under crystalline solid state, therefore form solvation Thing.If solvent is water, the solvate of formation is " hydrate ", if solvent is ethanol, the solvate of formation is For alcoholate.Hydrate is to combine to form hydrate by one or more hydrones and the material, wherein, hydrone State is H2O, such combination can form the hydrate for including one or more hydrones.
" pharmaceutically acceptable salt " of the present invention is in Berge, et al., " Pharmaceutically Acceptable salts ", J.Pharm.Sci., 66,1-19 are discussed in (1977), and for Pharmaceutical Chemist be it is aobvious and Be clear to, the salt is substantially avirulent, and pharmacokinetic property needed for providing, palatability, absorption, distribution, Metabolism or excretion etc..Compound of the present invention can have acidic-group, basic group or amphiprotic group, typically pharmaceutically Acceptable salt includes the salt being prepared by the compounds of this invention and acid reaction, such as：Hydrochloride, hydrobromate, sulfuric acid Salt, pyrosulfate, disulfate, sulphite, bisulfites, phosphate, dibasic alkaliine, dihydric phosphate, metaphosphoric acid Salt, pyrophosphate, nitrate, acetate, propionate, caprate, caprylate, formates, acrylates, isobutyrate, caproic acid Salt, enanthate, oxalates, malonate, succinate, suberate, benzoate, methyl benzoic acid salt, phthalic acid Salt, maleate, mesylate, tosilate, (D, L)-tartaric acid, citric acid, maleic acid, (D, L)-malic acid are rich Horse acid, succinic acid, succinate, lactate, fluoroform sulphonate, naphthalene -1- sulfonate, mandelate, acetonate, stearic acid Salt, ascorbate, salicylate.When the compounds of this invention contains acidic-group, its pharmaceutically acceptable salt can be with Including：Alkali metal salt, such as sodium or sylvite；Alkali salt, such as calcium or magnesium salts；Organic alkali salt, for example, with ammonia, alkyl ammonia The salt of the formation such as class, hydroxy alkyl Ammonia, amino acid (lysine, arginine), N-METHYL-ALPHA-L-GLUCOSAMINE.
" isomers " of the present invention refer to formula (I) compound of the present invention can have asymmetric center and racemic modification, Racemic mixture and single diastereoisomer, all these isomers, including stereoisomer, geometric isomer include In the present invention.Wherein, " isomers " of the present invention is preferably " stereoisomer ".In the present invention, formula (I) compound or Its salt is in the form of stereomeric in the presence of (for example, it contains one or more asymmetric carbon atoms), single alloisomerism Body (enantiomter and diastereoisomer) and their mixture are included within the scope of the invention.Present invention additionally comprises The compound or the independent isomers of salt that formula (I) represents, and the isomers inverted with wherein one or more chiral centres Mixture.The scope of the present invention includes：The mixture of stereoisomer, and the enantiomter or enantiomter purified/ The mixture of diastereoisomer enrichment.The present invention includes all enantiomters and all possible difference of non-corresponding isomers The mixture of the stereoisomer of combination.The present invention includes whole groups of the stereoisomer of all specific groups defined above Conjunction and subset.Present invention additionally comprises the geometric isomer of formula (I) compound or its salt, the geometric isomer includes cis-trans isomerism Body.
Without prejudice to the field on the basis of common sense, above-mentioned each optimum condition, can be combined, each preferably up to the present invention Example.
The reagents and materials used in the present invention are commercially available.
Brief description of the drawings
Fig. 1：The BV2 cells that andrographolide and the compounds of this invention suppress LPS inductions train IL6 and TNF α level in liquid, The compounds of this invention can reduce the generation of IL6 and TNF α to a certain degree under 10 μM of concentration, and effect is better than andrographolide.
Embodiment
The present invention is further illustrated below by the mode of embodiment, but does not therefore limit the present invention to the reality Apply among a scope.The experimental method of actual conditions is not specified in the following example, according to conventional methods and conditions, or according to business Product specification selects.
The structure of all compounds of the present invention can by nuclear magnetic resonance (1H NMR) and/or Mass Spectrometer Method (MS) identification.
1H nmr chemicals displacement (δ) records (10 with PPM-6).NMR is carried out by Bruker AVANCE-400 spectrometers.Close Suitable solvent is deuterochloroform (CDCl3), deuterated methanol (CD3OD), deuterated dimethyl sulfoxide (DMSO-d6), tetramethylsilane conduct Internal standard (TMS).
Algorithm (MS) is measured by Agilent 1200HPLC/6120 mass spectrographs, using XBridge C18,4.6 × 50mm, 3.5 μm, condition of gradient elution one：80-5% solvent orange 2 As1With 20-95% solvents B1(1.8 minutes), then 95% solvent B1With 5% solvent orange 2 A1(more than 3 minutes), percentage account for the percentage by volume of total solvent volume for a certain solvent.Solvent orange 2 A1： The aqueous solution of 0.01% trifluoroacetic acid (TFA)；Solvent B1：The acetonitrile solution of 0.01% trifluoroacetic acid；Percentage accounts for molten for solute The percentage by volume of liquid.Condition of gradient elution two：80-5% solvent orange 2 As2With 20-95% solvents B2(1.5 minutes), then 95% is molten Agent B2With 5% solvent orange 2 A2(more than 2 minutes), percentage account for the percentage by volume of total solvent volume for a certain solvent.Solvent orange 2 A2： The aqueous solution of the ammonium hydrogen carbonate of 10mM；Solvent B2：Acetonitrile.
The purifying of the compounds of this invention can use conventional silica gel plate, silica gel column chromatography or use high performance liquid chromatography (prep-HPLC) isolated and purified.
High performance liquid chromatograph (prep-HPLC) uses Shimadzu LC-20 preparative liquid chromatographies, and chromatographic column is：waters Xbridge Pre C18,10um, 19mm*250mm.Mobile phase A：(percentage is volume basis to 0.05% trifluoroacetic acid aqueous solution Number), Mobile phase B：Acetonitrile；Detection wavelength：214nm&254nm；Flow velocity：15.0mL/ minutes.
Thin layer silica gel plate (TLC) is Yantai Huanghai Sea HSGF254 or Qingdao GF254 silica gel plates.Silica gel column chromatography generally uses Yantai Huanghai Sea 200-300 mesh silica gel is as carrier.
Embodiment 1：The synthesis of compound 1-1
Step 1：Andrographolide (40g, 0.11mol) and ethanol (100mL) are added in there-necked flask (500mL), stirred Mix to dissolving clear state, be cooled to 0-10 DEG C, add hydrogen bromide (70mL, w/w：48%), keep under the temperature conditionss, react 24 it is small when, stop reaction, add sodium hydrate aqueous solution (6.0M) and adjust pH value between 6-7, add ethyl acetate (350mL), when stirring 12 is small, separates out a large amount of white solids, filters, and filter cake is recrystallized with ethyl acetate (100mL), filters, filter Compound 1.1 (35g, yield are obtained after biscuit is dry：88%) it is white solid.
Step 2：Compound 1.1 (35g, 0.10mol), acetone (70mL) and 2,2-dimethoxypropane (175mL) are added Enter into there-necked flask (500mL), be heated to 40-50 DEG C, keep at this temperature, when stirring 5-6 is small, TLC monitoring (just oneself Alkane/ethyl acetate=1/1), until raw material disappears, after reaction, reaction solution is transferred in single port bottle (500mL), is concentrated into It is dry；Ethyl acetate (175mL) is added into residue, 50~60 DEG C is heated to and dissolves, under heat-retaining condition, n-hexane is added dropwise (175mL), after being added dropwise, is cooled to 20~30 DEG C, separates out a large amount of white solids, filtering, and compound is obtained after filtration cakes torrefaction 1.2 (20g, yields：51%) it is white solid powder.
Step 3：By compound 1.2 (390mg, 1.00mmol), triethylamine (303mg, 3.00mmol) and DMAP (122mg, 1.00mmol) be dissolved in dichloromethane (4mL), reaction system be stirred at room temperature 0.5 it is small when after, add N- ethyl-N-methyl formyls Chlorine (242mg, 2.00mmol), reaction system be stirred at room temperature 3 it is small when, reaction solution is concentrated to give crude Compound 1.3, is directly used in down One step.
Step 4：Compound 1.3 is mixed in the in the mixed solvent of acetic acid (4mL) and water (1mL), and reaction system is stirred at room temperature 20 Minute, reaction solution concentration, purifies to obtain compound 1-1 (35mg, two step yields with prep-HPLC：8%) it is white solid.
1H NMR(400MHz,CD3OD):δ 6.81 (td, J=6.8,1.6Hz, 1H), 5.97 (d, J=5.6Hz, 1H), 4.80-4.86 (m, 2H, overlapped with water signal), 4.58 (dd, J=11.0,6.0Hz, 1H), 4.31 (d, J=11.2Hz, 1H), 4.11 (d, J=11.2Hz, 1H), 3.33-3.42 (m, 2H), 3.02-3.19 (m, 2H), 2.91 (d, J=8.6Hz, 3H), 1.98-2.16 (m, 2H), 1.68-1.88 (m, 4H), 1.58 (s, 3H), 1.43-1.53 (m, 1H), 1.22- 1.32(m,2H),1.20(s,3H),1.08-1.16(m,3H),0.98(s,3H)。
m/z:[M+NH4]+453.1
Embodiment 2：The synthesis of compound 1-2
Using the synthetic method of 1 compound 1-1 of embodiment, the N- ethyl-N-methyl formyl chlorides in step 1 are replaced with into 4- Morpholine formyl chloride obtains compound 1-2:
1H NMR(400MHz,CD3OD):δ 6.82 (td, J=6.8,1.6Hz, 1H), 6.00 (d, J=5.8Hz, 1H), 4.58 (dd, J=11.2,5.8Hz, 1H), 4.34 (dd, J=11.1,1.8Hz, 1H), 4.11 (d, J=11.2Hz, 1H), 3.60-3.70(m,4H),3.35-3.50(m,6H),3.00-3.19(m,2H),2.05-2.11(m,2H),1.74-1.83(m, 4H),1.57(s,3H),1.30-1.53(m,3H),1.21(s,3H),0.97(s,3H)。
m/z:[M-H]-462.2
Embodiment 3：The synthesis of compound 2-1
Step 1：By compound 1.2 (390mg, 1.00mmol), triphenylphosphine (393mg, 1.50mmol) and to formic acid uncle Butyl ester phenol (291mg, 1.50mmol) is dissolved in dry tetrahydrofuran (4mL), be cooled to 0 DEG C be added dropwise DIAD (303m g, 1.50mmol), reaction system is stirred overnight at room temperature, and reaction solution concentration, residue purifies (petroleum ether with silica gel column chromatography：Acetic acid Ethyl ester=3:1) compound 2.1 (410mg, yield are obtained：72%) it is faint yellow solid.
Step 2：Compound 2.1 (200mg, 0.353mmol) is mixed in the in the mixed solvent of acetic acid (2mL) and water (0.5mL), Reaction system is stirred at room temperature 20 minutes, and reaction solution concentration, purifies to obtain compound 2-1 (15mg, yield with prep-HPLC：6%) it is White solid.
1H NMR(400MHz,CD3OD):δ 7.96 (d, J=8.8Hz, 2H), 7.02 (d, J=8.8Hz, 2H), 6.88 (td, J=6.4,1.2Hz, 1H), 5.85 (d, J=5.2Hz, 1H), 4.71 (dd, J=10.8,5.6Hz, 1H), 4.38 (dd, J= 10.8,1.3Hz, 1H), 4.08 (d, J=11.2Hz, 1H), 3.32-3.40 (m, 2H), 2.94-3.12 (m, 2H), 1.98-2.10 (m,2H),1.72-1.83(m,4H),1.59(s,9H),1.56(s,3H),1.38-1.50(m,1H),1.12-1.26(m,5H), 0.89(s,3H)。
m/z:[M+NH4]+543.9
Embodiment 4：The synthesis of compound 2-2
Using the synthetic method of 3 compound 2-1 of embodiment, t-butyl formate phenol will be replaced with to cyanogen in step 1 Base phenol obtains compound 2-2:
1H NMR(400MHz,CD3OD):δ 7.74 (d, J=6.8Hz, 2H), 7.12 (d, J=6.8Hz, 2H), 6.90 (t, J =6.8Hz, 1H), 5.87-5.91 (m, 1H), 4.68-4.75 (m, 1H), 4.37 (d, J=10.8Hz, 1H), 4.09 (d, J= 10.4Hz,1H),3.48-3.32(m,2H),2.95-3.14(m,2H),2.04(s,2H),1.72-1.88(m,4H),1.56(s, 3H),1.40-1.52(m,1H),1.15-1.25(m,5H),0.90(s,3H)。
m/z:[M+NH4]+468.9
Embodiment 5：The synthesis of compound 3.2
Step 1：Add successively into n,N-Dimethylformamide (50mL) solution of 4- 4-hydroxy-benzonitriles (2.0g, 0.02mol) Enter ammonium chloride (9.0g, 0.16mol) and sodium azide (2.2g, 0.03mol), reaction system is stirred overnight at 120 DEG C.Will Reaction system is cooled to room temperature, and is then poured into frozen water, and pH to 2.5, obtained mixture acetic acid second are adjusted with hydrochloric acid (1M) Ester (50mL × 2) extracts, and merges organic phase, respectively with water and saturated common salt water washing, separates organic phase, is done with anhydrous sodium sulfate It is dry, filter, be concentrated to give compound 3.1 (2.3g, yield：72%) it is buff white solid.
Step 2：Triethylamine is separately added into dichloromethane (20mL) solution of compound 3.1 (2.0g, 12.3mmol) (2.5g, 24.7mmol) and Boc2O (3.0g, 13.7mmol), by reaction system be stirred at room temperature 12 it is small when.Then water is used (10mL × 2) washing reaction system, separates organic phase, with anhydrous sodium sulfate drying, filtering, concentration, residue silica gel column layer Analysis (petrol ether/ethyl acetate=1/1) purifies to obtain compound 3.2 (1.6g, yield：50%) it is buff white solid.
Embodiment 6：The synthesis of compound 2-3
Step 1：By compound 1.1 (8.0g, 22.8mmol), benzaldehyde dimethyl acetal (6.95g, 45.6mmol) and to first Benzene sulfonic acid pyridine hydrochloride (PPTS) (0.29g, 1.4mmol) is dissolved in dichloromethane (80mL), and reaction system is at room temperature Stir 18 it is small when.Then reaction solution is washed with water, separates organic phase, and with anhydrous sodium sulfate is dry, filtering, concentration.Residual Thing silica gel column chromatography (petrol ether/ethyl acetate=3/1) purifying obtains compound 3.3 (5.1g, yield：51%) it is solid for white Body.
Step 2：By compound 3.3 (200mg, 0.46mmol), triphenylphosphine (181mg, 0.69mmol) and compound 3.2 (180mg, 0.69mmol) is dissolved in dry tetrahydrofuran (5mL), is cooled to 0 DEG C, states in mixture be added dropwise then up DIAD (139.5mg, 0.69mmol), reaction system is stirred overnight at room temperature, and then concentrates reaction solution, residue silica gel column layer Analysis (petrol ether/ethyl acetate=3/1) purifies to obtain compound 3.4 (124mg, yield：36%) it is pale yellow oil.
m/z:[M+H2O]+699.8
Step 3：Compound 3.4 (20mg, 0.029mmol) and a hydration p-methyl benzenesulfonic acid (11mg, 0.06mmol) is molten In ethanol, 70 DEG C of reaction system stirs 3 days solution, then concentrates reaction solution, and residue purifies to obtain compound with prep-HPLC 2-3 (0.8mg, yield：6%) it is white solid.
m/z:[M+H2O]+512.4
Biological test embodiment：
Embodiment 1：Anti-inflammatory activity in the BV2 microglia inflammatory models of LPS inductions
First, cell is handled
For gene expression detection and ELISA：In advance~16h paving cells, 24 orifice plates, 200,000/hole；Experimental group：100ng/ MlLPS+DMSO or respective compound processing cell；Control group：DMSO same amount of with experimental group handles cell；Train liquid product： 400 μ l/ holes；
2nd, RNA extractings and RT-PCR
1. after compound processing cell 6h, old training liquid is sucked, adds trizol cell lysis, 500 μ l/ holes are blown even, are transferred to EP is managed；
2. adding 100 μ l CHCl3, mixing 30 times of turning upside down, is stored at room temperature 10min；
3. centrifugation, 4 DEG C, 12000rpm, 15min；
4. taking 200 μ l supernatants into new EP pipes, add 350 μ l isopropanols respectively, mixing 20 times of turning upside down, -20 DEG C quiet Put 20min；
5. centrifugation, 4 DEG C, 12000rpm, 15min；
6. abandoning supernatant, 75% ethanol of 1ml is added, is turned upside down several times, washing precipitation；
7. centrifugation, 4 DEG C, 12000rpm, 5min；
8. abandoning supernatant, inversion is dried；
9. adding the piping and druming of 30 μ l DEPC water to mix, dissolving precipitation on ice is placed in, surveys RNA concentration；
10.RT-PCR：
(1) RT-PCR is formulated
Reagent Volume
oligo dN6(0.1μg/μl) 1μl
10mM dNTP 1μl
Template RNA 1μg
DEPC H2O 13μl-V(RNA)
It is total 15μl
(2) 70 DEG C, 5min；1min is placed on ice；
(3) 4 μ 5 × RT of l buffer, 1 μ l M-MLVR are added；Mix；25 DEG C of placement 10min；
(4) 42 DEG C, 50min；
(5) 95 DEG C, 5min.
3rd, qPCR
1.qPCR is formulated：
2×PCR mix 12.5μl
Template (20 times of RT product dilutions) 4μl
Primers F/R(2.5μM/2.5μM) 4μl
Water 4.5μl
It is total 25μl
2. response procedures：
4th, ELISA (being up to section)
1. after compound processing cell 24h, transfer training liquid to EP is managed；
2. centrifugation, 12000rpm, 5min, supernatant are transferred to new EP pipes；
3. subsequent operation is carried out for IL6 and TNF α ELISA kit specifications according to up to section.
Experimental result：LPS processing can cause BV2 (microglia system), and be inflamed reaction, one of them typical table It is now the generation increase of inflammatory factor (IL1 β, IL6 etc.).Therefore, the BV2 inflammatory models induced first with LPS, pass through qPCR To evaluate, the suppression of the compounds of this invention is scorching to be acted on the expression of detection IL1 β and IL6.On this basis, it is further with ELISA The effect that the compounds of this invention generates IL6 and TNF α at 10 μM is demonstrated, the results are shown in Table 1 and Fig. 1.
Table 1：Percentage is the expression of compound treatment group inflammatory factor compared with reference group；" ++ " is to inflammatory Factor inhibition is best, and secondly, "-" is not detect positive effect to "+".
Table 1
Embodiment 2：Cell toxicity test
Detected for ATP-GLO：BV2 cells：16h spreads cell, 96 orifice plates, 30,000/hole in advance；Experimental group：Respective compound Handle cell；Control group：DMSO same amount of with experimental group handles cell；Train liquid product：200 μ l/ holes
ATP-GLO is tested：
1. after compound processing cell 24h, old training liquid is sucked, adds ATP-GLO lysates, 100 μ l/ holes；
2. lysis at room temperature cell 10min；
3. lysate is shifted into white 96 orifice plates, microplate reader detection Cell titer glo luminescence.
Experimental result：Influence of the compounds of this invention to BV2 cytoactives have detected by ATP-GLO experiments, as a result show Show that all test-compounds have not significant impact cytoactive in 10 μM and lower concentration and show that compound is not bright in itself Aobvious cytotoxicity.

Claims (18)

1. a kind of andrographolide class compound (I), its isomers, prodrug, solvate or pharmaceutically acceptable salt；
Wherein,
A and b is separately singly-bound or double bond, and is double bond or singly-bound during a and b differences；
X is-OR5Or-SR6；
Y and Z is separately selected from-O- or-NH-；
R1And R2Separately it is selected from hydrogen or alkyl；
R3And R4Separately selected from hydrogen, alkyl, haloalkyl ,-Si (Rc)3、-C(O)Rc、-SO3M；M is hydrogen, sodium or potassium；Or Person R3And R45-8 membered heterocycloalkyls are interconnected to form, the Heterocyclylalkyl further can also be selected from Si, S containing 1~2 (O)0-2Or the hetero atom or group of N atoms；The Heterocyclylalkyl is unsubstituted or further by 1~4 selected from alkyl, halogen Element, haloalkyl, hydroxy alkyl, alkoxyalkyl, alkoxy, amino, the substituent substitution of aminoalkyl or oxo base are in office Meaning position；
R5For substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted Heterocyclylalkyl, substitution or Unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyl-alkyl, substituted or unsubstituted heterocycle Alkyl-alkyl, substituted or unsubstituted aryl alkyl, substituted or unsubstituted heteroaryl alkyl, Ra、-C(O)Rb、-C(O) NRbRc、-C(O)ORc、-S(O)2Rb、-S(O)2NRcRd、-NRcRd、-(CH2)nORa；
R6For hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted Heterocyclylalkyl, substitution It is or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyl-alkyl, substituted or unsubstituted miscellaneous Cycloalkyl-alkyl, substituted or unsubstituted aryl alkyl, substituted or unsubstituted heteroaryl alkyl ,-C (O) Rb、-C(O) NRbRc、-C(O)ORcOr-(CH2)nORa；
R5Or R6In, when the substituted alkyl, substitution cycloalkyl, substitution Heterocyclylalkyl, substitution aryl, substitution it is miscellaneous Aryl, the cycloalkyl-alkyl of substitution, the hetercycloalkylalkyl of substitution, the aryl alkyl of substitution or substituted heteroaryl alkyl quilt Can be by 1~4 selected from halogen, C during substitution1-4Alkyl, halo C1-3Alkyl, C1-3Alkoxy, halo C1-3Alkoxy, C2-6Alkenyl, C2-6Alkynyl, C3-6Cycloalkyl, 3-6 membered heterocycloalkyls, phenyl, 5-6 unit's heteroaryls ,-NO2、-CN、-ORc、-SRc、-OC(O)Rc、- OC(O)NRcRd、-NRcRd、-N(Rc)C(O)Rd、-N(Rc)S(O)2Rd、-N(Rc)S(O)2NRcRd、-N(Rc)C(O)NRcRd、-S (O)2NRcRd、-S(O)0-2Rc、-OP(O)(O-Rc)2、-C(O)Rc、-C(O)ORcOr-C (O) NRcRdSubstituent substitution it is in office Meaning position；
RaFor glycyl-, L- alanyls-, L- leucyls-, L- valyls-, L- isoleucyl-s-, etc. amino acid residue；
RbFor hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted Heterocyclylalkyl, substitution It is or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyl-alkyl, substituted or unsubstituted miscellaneous Cycloalkyl-alkyl, substituted or unsubstituted aryl alkyl, substituted or unsubstituted heteroaryl alkyl；When the substituted alkyl, Substituted cycloalkyl, the Heterocyclylalkyl of substitution, the aryl of substitution, the heteroaryl of substitution, the cycloalkyl-alkyl of substitution, substitution it is miscellaneous Can be by 1~4 selected from halogen, C when cycloalkyl-alkyl, the aryl alkyl of substitution or substituted substituted heteroaryl alkyl1-4Alkane Base, halo C1-3Alkyl, C1-3Alkoxy, halo C1-3Alkoxy, C2-6Alkenyl, C2-6Alkynyl, C3-6Cycloalkyl, 3-6 circle heterocycles alkane Base, phenyl, 5-6 unit's heteroaryls ,-NO2、-CN、-ORc、-SRc、-OC(O)Rc、-OC(O)NRcRd、-NRcRd、-N(Rc)C(O) Rd、-N(Rc)S(O)2Rd、-N(Rc)S(O)2NRcRd、-N(Rc)C(O)NRcRd、-S(O)2NRcRd、-S(O)0-2Rc、-OP(O)(O- Rc)2、-C(O)Rc、-C(O)ORcOr-C (O) NRcRdSubstituent substitution at an arbitrary position；
RcAnd RdSeparately selected from hydrogen, C1-6Alkyl, halo C1-3Alkyl, C1-3Alkoxy, halo C1-3Alkoxy, C2-6Alkene Base, C2-6Alkynyl, C3-6Cycloalkyl, 3-6 membered heterocycloalkyls, phenyl or 5-6 unit's heteroaryls.
Alternatively, RcAnd RbOr RdWith forming 3-8 membered heterocycloalkyls together with the N atoms that they are connected jointly, the Heterocyclylalkyl may be used also Further N, O, S, S (O) are selected from containing 1~32Hetero atom, the 3-8 membered heterocycloalkyls for it is unsubstituted or further by 1~3 is selected from alkyl, halogen, haloalkyl, hydroxy alkyl, alkoxyalkyl, alkoxy, amino, aminoalkyl or oxo base Substituent substitution at an arbitrary position；
N is 1~6 integer.
2. andrographolide class compound (I) as claimed in claim 1, its isomers, prodrug, solvate or pharmaceutically Acceptable salt, it is characterised in that：R1For hydrogen or C1-6Alkyl；
And/or R2For hydrogen or C1-6Alkyl；
And/or R3For hydrogen, C1-6Alkyl, halo C1-3Alkyl ,-Si (Rc)3、-C(O)Rc、-SO3M；M is hydrogen, sodium or potassium；
And/or R4For hydrogen, C1-6Alkyl, halo C1-3Alkyl ,-Si (Rc)3、-C(O)Rc、-SO3M；M is hydrogen, sodium or potassium；Or R3 And R45-8 membered heterocycloalkyls are interconnected to form, the Heterocyclylalkyl further can also be selected from Si, S (O) containing 1-20-2、 Or the hetero atom or group of N atoms；The Heterocyclylalkyl is unsubstituted or is further selected from C by 1-31-4Alkyl, halogen, Halo C1-3Alkyl, hydroxyl C1-3Alkyl, C1-3Alkoxy C1-3Alkyl, C1-3Alkoxy, amino, amino C1-3Alkyl or oxo base One or more of substituent substitutes at an arbitrary position.
3. andrographolide class compound (I) as claimed in claim 1, its isomers, prodrug, solvate or pharmaceutically Acceptable salt, it is characterised in that：R5For substituted or unsubstituted C1-6Alkyl, substituted or unsubstituted C3-8Cycloalkyl, substitution Or unsubstituted 3-8 membered heterocycloalkyls, substituted or unsubstituted phenyl, substituted or unsubstituted 5-6 unit's heteroaryls, substitution or not Substituted C3-8Cycloalkyl C1-3Alkyl, substituted or unsubstituted 3-8 membered heterocycloalkyls C1-3Alkyl, substituted or unsubstituted phenyl C1-3Alkyl, substituted or unsubstituted 5-6 unit's heteroaryls C1-3Alkyl, Ra、-C(O)Rb、-C(O)NRbRc、-C(O)ORc、-S(O)2Rb、-S(O)2NRcRd、-NRcRd、-(CH2)nORa；
R6For substituted or unsubstituted C1-6Alkyl, substituted or unsubstituted C3-8Cycloalkyl, substituted or unsubstituted 3-8 circle heterocycles Alkyl, substituted or unsubstituted phenyl, substituted or unsubstituted 5-6 unit's heteroaryls, substituted or unsubstituted C3-8Cycloalkyl C1-3 Alkyl, substituted or unsubstituted 3-8 membered heterocycloalkyls C1-3Alkyl, substituted or unsubstituted phenyl C1-3Alkyl, substitution do not take The 5-6 unit's heteroaryls C in generation1-3Alkyl ,-C (O) Rb、-C(O)NRbRc、-C(O)ORcOr-(CH2)nORa；
RbFor hydrogen, substituted or unsubstituted C1-6Alkyl, substituted or unsubstituted C3-8Cycloalkyl, substituted or unsubstituted 3-8 members are miscellaneous Cycloalkyl, substituted or unsubstituted phenyl, substituted or unsubstituted 5-6 unit's heteroaryls, substituted or unsubstituted C3-8Cycloalkyl C1-3Alkyl, substituted or unsubstituted 3-8 membered heterocycloalkyls C1-3Alkyl, substituted or unsubstituted phenyl C1-3Alkyl or substitution or Unsubstituted 5-6 unit's heteroaryls C1-3Alkyl；
Ra、RcAnd RdDefinition it is as claimed in claim 1.
4. as claims 1 to 3 any one of them andrographolide class compound (I), its isomers, prodrug, solvate, Or pharmaceutically acceptable salt, it is characterised in that：When a is double bond, b is singly-bound.
5. as claims 1 to 3 any one of them andrographolide class compound (I), its isomers, prodrug, solvate, Or pharmaceutically acceptable salt, it is characterised in that：When a is singly-bound, b is double bond.
6. as claims 1 to 3 any one of them andrographolide class compound (I), its isomers, prodrug, solvate, Or pharmaceutically acceptable salt, it is characterised in that：Its general structure is：
Wherein, * is expressed as R configurations or S configurations；
R2、R3、R4And R5Definition as described in any one of claims 1 to 3.
7. as claims 1 to 3 any one of them andrographolide class compound (I), its isomers, prodrug, solvate, Or pharmaceutically acceptable salt, it is characterised in that：Its general structure is：
Wherein, * is expressed as R configurations or S configurations；
A rings are phenyl ring or 5-6 member hetero-aromatic rings；
R7For halogen, C1-4Alkyl, halo C1-3Alkyl, C1-3Alkoxy, halo C1-3Alkoxy, C2-6Alkenyl, C2-6Alkynyl, C3-6Ring Alkyl, 3-6 membered heterocycloalkyls, phenyl, 5-6 unit's heteroaryls ,-NO2、-CN、-ORc、-SRc、-OC(O)Rc、-OC(O)NRcRd、- NRcRd、-N(Rc)C(O)Rd、-N(Rc)S(O)2Rd、-N(Rc)S(O)2NRcRd、-N(Rc)C(O)NRcRd、-S(O)2NRcRd、-S (O)0-2Rc、-OP(O)(O-Rc)2、-C(O)Rc、-C(O)ORcOr-C (O) NRcRd；
T is 1,2 or 3；
R1、R2、R4、RcAnd RdDefinition as described in any one of claims 1 to 3.
8. andrographolide class compound (I) as claimed in claim 7, its isomers, prodrug, solvate or pharmaceutically Acceptable salt, it is characterised in that：R2For CH3；
And/or R3For H, R4For H.
9. as claims 1 to 3 any one of them andrographolide class compound (I), its isomers, prodrug, solvate, Or pharmaceutically acceptable salt, it is characterised in that：Its general structure is：
Wherein, * is expressed as R configurations or S configurations；
R2、R3、R4、RbAnd RcDefinition as described in any one of claims 1 to 3.
10. andrographolide class compound (I) as claimed in claim 9, its isomers, prodrug, solvate or pharmaceutically Acceptable salt, it is characterised in that：R2For CH3；
And/or R3For H, R4For H.
11. andrographolide class compound (I) as claimed in claim 1, its isomers, prodrug, solvate or pharmaceutically Acceptable salt, it is characterised in that：The compound as shown in formula (I) is following any compound：
12. such as claim 1~11 any one of them andrographolide class compound (I), its isomers, prodrug, solvation The preparation method of thing or pharmaceutically acceptable salt, it is following either method：
Method one：The preparation method includes the following steps：1) in solvent, under the action of alkali, by compound I.2 with N (Rb) (Rc) COCl or RbCOCl carries out nucleophilic substitution；2) in solvent, in acid condition, the compound I-1 that step 1) is obtained Or I-2 carries out deprotection reaction and obtains Ia or Ib；
Wherein, R ' is phenyl, and R " is H；Or R ' and R " is methyl；
Method two：The preparation method includes the following steps：1) in solvent, by compound 1.2 withCarry out Mitsunobu reacts；2) in solvent, in acid condition, the compound I-3 that step 1) obtains is subjected to deprotection reaction and is obtained To Ic；
Wherein, R ' is phenyl, and R " is H；Or R ' and R " is methyl.
13. preparation method as claimed in claim 12, it is characterised in that：It is described as described in formula 1.2 in method one or method two Compound can be prepared by the following method：
Wherein, the preparation method includes the following steps：1) in solvent, by andrographolide aqueous solution of hydrogen bromide effect Lower 17 generations rearrangement reaction；2) 3 of compound 1.1 that step 1) obtains and 19 hydroxyls are obtained into compound by protection 1.2；
Wherein, R ' is phenyl, and R " is H；Or R ' and R " is methyl.
14. a kind of pharmaceutical composition, it includes the active component of therapeutically effective amount and pharmaceutically acceptable auxiliary material；The work Property component include such as claim 1~11 any one of them andrographolide class compound (I), its isomers, prodrug, solvent Compound or pharmaceutically acceptable salt.
15. pharmaceutical composition as claimed in claim 14, it is characterised in that：It is described pharmaceutically in described pharmaceutical composition The auxiliary material of receiving includes pharmaceutically acceptable carrier, diluent and/or excipient.
16. as claim 1~11 any one of them compound shown in formula I, its isomers, prodrug, solvate or Pharmaceutically acceptable salt, or pharmaceutical composition as described in claims 14 or 15 is in preparing and treating inflammation disease medicine Using.
17. application as claimed in claim 16, it is characterised in that：The inflammation disease is included by cause of diseases such as bacterium, viruses Inflammation, inflammation disease or the inflammation disease as caused by radiation damage as caused by autoimmune response caused by body-sensing contaminates.
18. application as claimed in claim 17, it is characterised in that：The virus includes the various viruses of hand-foot-and-mouth disease (include but not limited to：Enterovirus EV71, Coxsackie virus CA16 etc.), hepatitis viruse (include but not limited to：Hepatitis A, hepatitis B, third Hepatovirus), AIDS virus etc.；Inflammation disease caused by the autoimmune response includes：It is rheumatoid arthritis, systemic Lupus erythematosus, dermatomyositis, nodular vasculitis, empsyxis nephrotic syndrome, acute glomerulonephritis, primary film proliferative kidney Bead ephritis, primary biliary cirrhosis, autoimmune cholangitis, oneself immunity hepatitis, primary sclerotic bile duct Inflammation, Crohn disease, ulcerative colitis, chronic obstructive pulmonary disease etc.；Inflammation caused by the radioactive damage includes：Radioactivity Esophagitis, radiation enteritis, radiation thyroiditis, radioactivity osteitis, Inflammation of Radioactive Oral Cavity, radiation_induced pleurisy, radioactivity Dermatitis, radiation pneumonitis, radioactivity vaginitis, radiocystitis etc..
CN201710997767.XA 2016-10-24 2017-10-24 Andrographolide compound, preparation method thereof, pharmaceutical composition and application Active CN107973764B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201610937799 2016-10-24
CN2016109377996 2016-10-24

Publications (2)

Publication Number Publication Date
CN107973764A true CN107973764A (en) 2018-05-01
CN107973764B CN107973764B (en) 2023-08-22

Family

ID=62012595

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201710997767.XA Active CN107973764B (en) 2016-10-24 2017-10-24 Andrographolide compound, preparation method thereof, pharmaceutical composition and application

Country Status (1)

Country Link
CN (1) CN107973764B (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112645937A (en) * 2020-12-28 2021-04-13 深圳湾实验室 Aza spiro ring and polycyclic andrographolide compound, preparation method thereof, pharmaceutical composition and application thereof
CN113582951A (en) * 2020-04-30 2021-11-02 江西青峰药业有限公司 10- (S) -17-hydrogen-7-dehydro-andrographolide and industrial chromatographic preparation method and application thereof
CN113620914A (en) * 2020-05-08 2021-11-09 江西青峰药业有限公司 Andrographolide derivative and industrial chromatographic preparation method and application thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020016363A1 (en) * 2000-05-05 2002-02-07 Dr. Reddy's Research Foundation Novel anticancer compounds : process for their preparation and pharmaceutical compositions containing them
US20060106098A1 (en) * 2004-11-18 2006-05-18 Advanced Gene Technology, Corp. Andrographolide and its derivatives as TNF-alpha antagonists
CN101012211A (en) * 2007-02-06 2007-08-08 中国药科大学 Substituted andrographolide derivative, preparing method and pharmaceutical compound thereof
CN103145657A (en) * 2012-04-12 2013-06-12 江西青峰药业有限公司 17-hydro-9-dehydroandrographolide compound and its preparation method and use in drug preparation
CN103224492A (en) * 2013-04-15 2013-07-31 南京工业大学 14-aryl ether andrographolide derivatives and preparation method and application thereof
CN104856987A (en) * 2015-01-22 2015-08-26 南京工业大学 Application of 14-aryl ether andrographolide derivative in antibacterial field

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020016363A1 (en) * 2000-05-05 2002-02-07 Dr. Reddy's Research Foundation Novel anticancer compounds : process for their preparation and pharmaceutical compositions containing them
US20060106098A1 (en) * 2004-11-18 2006-05-18 Advanced Gene Technology, Corp. Andrographolide and its derivatives as TNF-alpha antagonists
CN101012211A (en) * 2007-02-06 2007-08-08 中国药科大学 Substituted andrographolide derivative, preparing method and pharmaceutical compound thereof
CN103145657A (en) * 2012-04-12 2013-06-12 江西青峰药业有限公司 17-hydro-9-dehydroandrographolide compound and its preparation method and use in drug preparation
CN103224492A (en) * 2013-04-15 2013-07-31 南京工业大学 14-aryl ether andrographolide derivatives and preparation method and application thereof
CN104856987A (en) * 2015-01-22 2015-08-26 南京工业大学 Application of 14-aryl ether andrographolide derivative in antibacterial field

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
MAYUR M.UTTEKAR等: "Anti-HIV activity of semisynthetic derivatives of andrographolide and computational study of HIV-1 gp120 protein binding", 《EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY》 *
MAYUR M.UTTEKAR等: "Anti-HIV activity of semisynthetic derivatives of andrographolide and computational study of HIV-1 gp120 protein binding", 《EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY》, vol. 56, 24 July 2012 (2012-07-24), pages 4 *
W.R.CHAN等: "THE STRUCTURE AND STEREOCHEMISTRY OF NEOANDROGRAPHOLIDE, A DITERPENE GLUCOSIDE FROM ANDROGRAPHIS PANICULATA NEES", 《TETRAHEDRON》 *
W.R.CHAN等: "THE STRUCTURE AND STEREOCHEMISTRY OF NEOANDROGRAPHOLIDE, A DITERPENE GLUCOSIDE FROM ANDROGRAPHIS PANICULATA NEES", 《TETRAHEDRON》, vol. 27, 31 December 1971 (1971-12-31), pages 5084 *
徐顺: "穿心莲内酯衍生物的构效关系的理论研究", 《中国优秀硕士学位论文全文数据库》, no. 02, pages 1 - 65 *
马长沙等: "穿心莲内酯及其衍生物药理活性研究", 《吉林中医药》, pages 77 - 81 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113582951A (en) * 2020-04-30 2021-11-02 江西青峰药业有限公司 10- (S) -17-hydrogen-7-dehydro-andrographolide and industrial chromatographic preparation method and application thereof
WO2021218148A1 (en) * 2020-04-30 2021-11-04 江西青峰药业有限公司 10-(s)-17-hydrogen-7-dehydro-andrographolidume, industrial chromatography-based preparation method therefor, and use thereof
CN113582951B (en) * 2020-04-30 2024-03-19 江西青峰药业有限公司 10- (S) -17-hydrogen-7-dehydroandrographolide and industrial chromatographic preparation method and application thereof
CN113620914A (en) * 2020-05-08 2021-11-09 江西青峰药业有限公司 Andrographolide derivative and industrial chromatographic preparation method and application thereof
CN113620914B (en) * 2020-05-08 2024-03-19 江西青峰药业有限公司 Andrographolide derivative and industrial chromatographic preparation method and application thereof
CN112645937A (en) * 2020-12-28 2021-04-13 深圳湾实验室 Aza spiro ring and polycyclic andrographolide compound, preparation method thereof, pharmaceutical composition and application thereof

Also Published As

Publication number Publication date
CN107973764B (en) 2023-08-22

Similar Documents

Publication Publication Date Title
CN105884780B (en) Polycyclic compound, its pharmaceutical composition and application
KR20190003572A (en) Benzazepine derivatives, their preparation, drug compositions and applications
JP2000510848A (en) Benzofurancarboxamides and their therapeutic use
WO2022017533A1 (en) Compound useful as cdk7 kinase inhibitor and use thereof
CN106083978A (en) Sulfonyl amino carbonyl derivant, its pharmaceutical composition and application
JP4309475B2 (en) New benzofuran-4-carboxamide
CN107674013A (en) Polycyclic compound, its preparation method, pharmaceutical composition and application
JP2022512900A (en) Development and use of acetylation lighter inhibitors
CA2838703C (en) Indanone derivatives, pharmaceutically acceptable salts or optical isomers thereof, preparation method for same, and pharmaceutical compositions containing same as active ingredient for preventing or treating viral diseases
JP2000510865A (en) Quinolinecarboxamides as inhibitors of TNF and PDE-IV
CN107973764A (en) Andrographolide class compound, its preparation method, pharmaceutical composition and application
KR20180041748A (en) PARP inhibitors, processes for preparing crystalline forms and uses thereof
CN107556244A (en) And cycle compound, its pharmaceutical composition and application
CN108148022A (en) Andrographolide class compound, its pharmaceutical composition and application
JP2000501411A (en) Benzofurancarboxamide and sulfonamide
JP2016512225A (en) Pyrrole derivatives as alpha 7NACHR modulators
JP2016145212A (en) Polymorphs of cddo ethyl ester and uses thereof
CN110156656A (en) Five yuan of heteroaromatic ring derivatives, preparation method, pharmaceutical composition and application
CN109721597B (en) Pyridoazepine derivative, and pharmaceutical composition and application thereof
JP2014534208A5 (en)
WO2011143444A2 (en) Diphenylbutypiperidine autophagy inducers
JP2020500184A (en) Phenyl and pyridinyl hydroxamic acids
WO2014134750A1 (en) 2,6,9-trisubstituted purine derivative and preparation method and use thereof
KR20230161976A (en) Antiviral heterocyclic compounds
WO2019079649A1 (en) Substituted pyrrolopyridines as inhibitors of activin receptor-like kinase

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20220216

Address after: 341000 East Avenue, Shahe Industrial Park Station, Zhanggong District, Ganzhou City, Jiangxi Province

Applicant after: JIANGXI QINGFENG PHARMACEUTICAL Co.,Ltd.

Address before: 341000 No. 8 East Avenue, Shahe Industrial Park Station, Ganzhou City, Jiangxi Province

Applicant before: JIANGXI QINGFENG PHARMACEUTICAL Co.,Ltd.

Applicant before: SHANGHAI DE NOVO PHARMATECH Co.,Ltd.

TA01 Transfer of patent application right
GR01 Patent grant
GR01 Patent grant